Christian Gerges
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christian Gerges has a total of 268 co-authors. Here are the top co-authors by number of shared publications:
- Irene Marthe Lang
Department of Internal Medicine II, Cardiology, Medical University of Vienna, Vienna, Austria
26 shared publications Mario Gerges
Department of Internal Medicine II, Division of Cardiology (C.G., M.G., I.S., R.S.-K., N.S.-S., I.M.L.), Medical University of Vienna, Austria
15 shared publicationsIrene M. Lang
Division of Cardiology, Department of Internal Medicine II, Vienna General Hospital, Medical University of Vienna , Vienna
9 shared publications- Marc Humbert
INSERM UMR_S 999, Assistance Publique Hôpitaux de Paris, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, Université Paris–Saclay , Le Kremlin Bicêtre
7 shared publications Nika Skoro-Sajer
Division of Cardiology, Department of Internal Medicine II, Vienna General Hospital, Medical University of Vienna , Vienna
7 shared publications- David Montani
INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
6 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (10) , 1685-1696
Haemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients
- 1 June 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (10) , 1685-1696
Open AccessHaemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients
- Open Access
- 28 May 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (5)
Effective Arterial Elastance Relates More Closely to Pulsatile Than Resistive Indices During Routine Hemodynamic Assessment of Inoperable CTEPH
- 28 May 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (5)
Open AccessEffective Arterial Elastance Relates More Closely to Pulsatile Than Resistive Indices During Routine Hemodynamic Assessment of Inoperable CTEPH
- Open Access
- 18 January 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (1)
Subcutaneous Treprostinil in PH Associated With Left Heart Disease or Chronic Lung Disease
Pulmonary hypertension (PH) associated with left heart disease (LHD‐PH) and pulmonary hypertension associated with chronic lung disease (CLD‐PH) are the most common PH subtypes but lack effective treatments. In a prospective cohort study, 90 patients (39 LHD‐PH, 51 CLD‐PH) with severe disease [pulmonary vascular resistance (PVR) > 5 Wood units and recent right heart failure (RHF)] were treated with subcutaneous Treprostinil (scTRE). Clinical, echocardiographic, and hemodynamic parameters were assessed at baseline and at 12 months; survival was tracked for 5 years. In LHD‐PH and CLD‐PH patients at 12 months, 6‐min walking distance (6MWD) improved by 88 m [64;112] and 52 m [22;89], respectively, World Health Organisation functional class (WHO FC) improved in 77% and 78% of patients and mean pulmonary artery pressure (mPAP) decreased by 5.78 mmHg and 9.05 mmHg, respectively. Tricuspid annular plane systolic excursion/systolic pulmonary artery pressure (TAPSE/sPAP) ratio improved in patients with CLD‐PH. Median scTRE dose at 12 months was 30 ng/kg/min. Overall survival at 5 years was 38.6% in LHD‐PH group and 49.7% in CLD‐PH group. Patients with baseline pulmonary arterial wedge pressure (PAWP) < 12 mmHg had better outcomes. Open‐label scTRE was associated with a spectrum of clinically relevant benefits in a select group of LHD‐PH and CLD‐PH patients recently hospitalized for RV failure and was well tolerated.
- 18 January 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (1)
Open AccessSubcutaneous Treprostinil in PH Associated With Left Heart Disease or Chronic Lung Disease
Pulmonary hypertension (PH) associated with left heart disease (LHD‐PH) and pulmonary hypertension associated with chronic lung disease (CLD‐PH) are the most common PH subtypes but lack effective treatments. In a prospective cohort study, 90 patients (39 LHD‐PH, 51 CLD‐PH) with severe disease [pulmonary vascular resistance (PVR) > 5 Wood units and recent right heart failure (RHF)] were treated with subcutaneous Treprostinil (scTRE). Clinical, echocardiographic, and hemodynamic parameters were assessed at baseline and at 12 months; survival was tracked for 5 years. In LHD‐PH and CLD‐PH patients at 12 months, 6‐min walking distance (6MWD) improved by 88 m [64;112] and 52 m [22;89], respectively, World Health Organisation functional class (WHO FC) improved in 77% and 78% of patients and mean pulmonary artery pressure (mPAP) decreased by 5.78 mmHg and 9.05 mmHg, respectively. Tricuspid annular plane systolic excursion/systolic pulmonary artery pressure (TAPSE/sPAP) ratio improved in patients with CLD‐PH. Median scTRE dose at 12 months was 30 ng/kg/min. Overall survival at 5 years was 38.6% in LHD‐PH group and 49.7% in CLD‐PH group. Patients with baseline pulmonary arterial wedge pressure (PAWP) < 12 mmHg had better outcomes. Open‐label scTRE was associated with a spectrum of clinically relevant benefits in a select group of LHD‐PH and CLD‐PH patients recently hospitalized for RV failure and was well tolerated.
- Open Access
- 18 January 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (1)
Prognostic Value of Acute Vasoreactivity in Chronic Thromboembolic Pulmonary Hypertension
Vasoreactivity, which refers to the reduction of mean pulmonary arterial pressure in response to inhaled vasodilators, is a well‐established metric for prognostication and treatment selection in patients with pulmonary arterial hypertension. However, the role of vasoreactivity in chronic thromboembolic pulmonary hypertension is less studied. We investigated whether vasoreactivity at time of diagnosis carries prognostic value in all patients with chronic thromboembolic pulmonary hypertension, and how it relates to the effect of long‐term pulmonary vasodilator treatments. Patients diagnosed with CTEPH were prospectively subjected to 40 ppm inhaled nitric oxide testing at the diagnostic right heart catheterization. Classic (acute decrease of mean pulmonary arterial pressure > 10 mmHg to a level below 40 mmHg, n = 25), absolute (acute decrease of by 10 mmHg, n = 47) and percent (acute decrease by 10%, n = 129, all with maintained cardiac output) definitions of vasoreactivity were examined in retrospect. The relationship between each definition and transplantation‐free survival was assessed with Cox regression models adjusted for baseline mPAP, age, sex, and WHO functional class. Patients ( n = 325) were observed over a median of 5.5 years (interquartile range 2.6–9.2). Vasoreactivity, by the percent definition, was associated with significantly improved adjusted 5‐year transplantation‐free survival (hazard ratio = 0.61, 95% confidence interval 0.38–0.97, p = 0.036). Among not operated patients (n = 174, 53.5%), vasodilator PH medications were associated with improved survival in vasoresponders (hazard ratio = 0.46, 95% confidence interval 0.22–0.96, p = 0.04), but had no impact on survival in non‐vasoresponders (hazard ratio = 0.67, 95% confidence interval 0.36–1.24, p = 0.20). Vasoreactivity at baseline catheterization carries prognostic value in CTEPH.
- 18 January 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (1)
Open AccessPrognostic Value of Acute Vasoreactivity in Chronic Thromboembolic Pulmonary Hypertension
Vasoreactivity, which refers to the reduction of mean pulmonary arterial pressure in response to inhaled vasodilators, is a well‐established metric for prognostication and treatment selection in patients with pulmonary arterial hypertension. However, the role of vasoreactivity in chronic thromboembolic pulmonary hypertension is less studied. We investigated whether vasoreactivity at time of diagnosis carries prognostic value in all patients with chronic thromboembolic pulmonary hypertension, and how it relates to the effect of long‐term pulmonary vasodilator treatments. Patients diagnosed with CTEPH were prospectively subjected to 40 ppm inhaled nitric oxide testing at the diagnostic right heart catheterization. Classic (acute decrease of mean pulmonary arterial pressure > 10 mmHg to a level below 40 mmHg, n = 25), absolute (acute decrease of by 10 mmHg, n = 47) and percent (acute decrease by 10%, n = 129, all with maintained cardiac output) definitions of vasoreactivity were examined in retrospect. The relationship between each definition and transplantation‐free survival was assessed with Cox regression models adjusted for baseline mPAP, age, sex, and WHO functional class. Patients ( n = 325) were observed over a median of 5.5 years (interquartile range 2.6–9.2). Vasoreactivity, by the percent definition, was associated with significantly improved adjusted 5‐year transplantation‐free survival (hazard ratio = 0.61, 95% confidence interval 0.38–0.97, p = 0.036). Among not operated patients (n = 174, 53.5%), vasodilator PH medications were associated with improved survival in vasoresponders (hazard ratio = 0.46, 95% confidence interval 0.22–0.96, p = 0.04), but had no impact on survival in non‐vasoresponders (hazard ratio = 0.67, 95% confidence interval 0.36–1.24, p = 0.20). Vasoreactivity at baseline catheterization carries prognostic value in CTEPH.
- 15 October 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (2) , 260-261
Lung transplantation for chronic thromboembolic pulmonary hypertension (CTEPH): A treatment of last resort
- 15 October 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (2) , 260-261
Lung transplantation for chronic thromboembolic pulmonary hypertension (CTEPH): A treatment of last resort
- Open Access
- 12 August 2025
- Published by Springer Nature in Zeitschrift für Pneumologie
- Vol. 22 (5) , 264-272
Management der pulmonalarteriellen Hypertonie
Zusammenfassung: Die pulmonalarterielle Hypertonie (PAH) ist eine seltene, progrediente Erkrankung mit hoher Morbidität und Mortalität. Die moderne PAH-Therapie verfolgt das Ziel, ein Low-risk-Profil zu erreichen und umfasst heute Kombinationstherapien mit Wirkstoffen, die an verschiedenen pathophysiologischen Signalwegen ansetzen. Neue Substanzen wie Sotatercept erweitern das therapeutische Spektrum. Dieser Beitrag gibt einen Überblick über den aktuellen Therapiealgorithmus inklusive der Bedeutung einer strukturierten Risikostratifikation, frühzeitigen Reevaluierung und Therapieeskalation. Darüber hinaus werden besondere klinische Situationen wie Schwangerschaft, perioperative Betreuung, Komorbiditäten, Medikamentenadhärenz und palliative Versorgung adressiert. Eine engmaschige Nachsorge in spezialisierten Zentren ist essenziell für den Therapieerfolg.
- 12 August 2025
- Published by Springer Nature in Zeitschrift für Pneumologie
- Vol. 22 (5) , 264-272
Open AccessManagement der pulmonalarteriellen Hypertonie
Zusammenfassung: Die pulmonalarterielle Hypertonie (PAH) ist eine seltene, progrediente Erkrankung mit hoher Morbidität und Mortalität. Die moderne PAH-Therapie verfolgt das Ziel, ein Low-risk-Profil zu erreichen und umfasst heute Kombinationstherapien mit Wirkstoffen, die an verschiedenen pathophysiologischen Signalwegen ansetzen. Neue Substanzen wie Sotatercept erweitern das therapeutische Spektrum. Dieser Beitrag gibt einen Überblick über den aktuellen Therapiealgorithmus inklusive der Bedeutung einer strukturierten Risikostratifikation, frühzeitigen Reevaluierung und Therapieeskalation. Darüber hinaus werden besondere klinische Situationen wie Schwangerschaft, perioperative Betreuung, Komorbiditäten, Medikamentenadhärenz und palliative Versorgung adressiert. Eine engmaschige Nachsorge in spezialisierten Zentren ist essenziell für den Therapieerfolg.
- 1 August 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (8) , e017935
3D Reconstruction of Pulmonary Vascular Lesions in Chronic Thromboembolic Pulmonary Hypertension
- 1 August 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (8) , e017935
3D Reconstruction of Pulmonary Vascular Lesions in Chronic Thromboembolic Pulmonary Hypertension
- Open Access
- 31 July 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (9) , 102022
Prognostic Value of Biomarkers in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy
- 31 July 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (9) , 102022
Open AccessPrognostic Value of Biomarkers in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy
- Open Access
- 29 July 2025
- Published by Wiley in Pulmonary Circulation
- Vol. 15 (3)
Development of a Novel, Pulmonary Endovascular Device to Treat Patients With Pulmonary Hypertension
Pulmonary hypertension (PH) carries a poor prognosis and a high mortality. Loss of pulmonary arterial compliance (PAC) plays a significant role in the development of PH and is an early predictor of mortality. Currently, there are no therapeutic options to overcome the loss of PAC. Aria CV (Saint Paul, MN) has developed a device to augment PAC. The device consists of a 20‐cc balloon and anchor that can be implanted in the pulmonary artery using a minimally invasive procedure, a catheter, and a gas reservoir. Computed tomography imaging of 46 patients from the ASPIRE database and cadaver studies (n = 7) were used to ascertain device fit and optimize surgical procedure. Aria CV devices (n = 6) were tested for simulated use, durability, and PAC augmentation. Animal studies were conducted to demonstrate device safety in the deflated state (n = 9), and gas embolism due to simulated balloon rupture (n = 5). A chronic bovine model of PH was used to demonstrate PAC augmentation (n = 3). Chronic animal studies (n = 8, 30‐days) were conducted to demonstrate long‐term device safety and biocompatibility per ISO 10993 standards. In‐silico fit and cadaver studies demonstrated that the device could be successfully implanted in the PA for a wide range of patients. In vitro and bovine models of PH demonstrated that the chronic Aria CV device enhanced PAC by > 0.4 ml/mmHg, which matched the PAC enhancement observed in 28 human patients with a short‐term Aria CV device. The device passed all required durability, safety, and biocompatibility testing and is enrolling patients in a Food and Drug Administration (FDA) approved clinical trial (ASPIRE PH, NCT04555161).
- 29 July 2025
- Published by Wiley in Pulmonary Circulation
- Vol. 15 (3)
Open AccessDevelopment of a Novel, Pulmonary Endovascular Device to Treat Patients With Pulmonary Hypertension
Pulmonary hypertension (PH) carries a poor prognosis and a high mortality. Loss of pulmonary arterial compliance (PAC) plays a significant role in the development of PH and is an early predictor of mortality. Currently, there are no therapeutic options to overcome the loss of PAC. Aria CV (Saint Paul, MN) has developed a device to augment PAC. The device consists of a 20‐cc balloon and anchor that can be implanted in the pulmonary artery using a minimally invasive procedure, a catheter, and a gas reservoir. Computed tomography imaging of 46 patients from the ASPIRE database and cadaver studies (n = 7) were used to ascertain device fit and optimize surgical procedure. Aria CV devices (n = 6) were tested for simulated use, durability, and PAC augmentation. Animal studies were conducted to demonstrate device safety in the deflated state (n = 9), and gas embolism due to simulated balloon rupture (n = 5). A chronic bovine model of PH was used to demonstrate PAC augmentation (n = 3). Chronic animal studies (n = 8, 30‐days) were conducted to demonstrate long‐term device safety and biocompatibility per ISO 10993 standards. In‐silico fit and cadaver studies demonstrated that the device could be successfully implanted in the PA for a wide range of patients. In vitro and bovine models of PH demonstrated that the chronic Aria CV device enhanced PAC by > 0.4 ml/mmHg, which matched the PAC enhancement observed in 28 human patients with a short‐term Aria CV device. The device passed all required durability, safety, and biocompatibility testing and is enrolling patients in a Food and Drug Administration (FDA) approved clinical trial (ASPIRE PH, NCT04555161).